These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 17029149)

  • 21. A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy.
    Alimenti A; Forbes JC; Oberlander TF; Money DM; Grunau RE; Papsdorf MP; Maan E; Cole LJ; Burdge DR
    Pediatrics; 2006 Oct; 118(4):e1139-45. PubMed ID: 16940166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compliance with antiretroviral regimens.
    Laurence J
    AIDS Read; 2001 Apr; 11(4):177, 181. PubMed ID: 11392675
    [No Abstract]   [Full Text] [Related]  

  • 23. Initial treatment of HIV infection: randomized trials with clinical end points are still needed.
    Hughes MD
    J Infect Dis; 2006 Sep; 194(5):542-4. PubMed ID: 16897649
    [No Abstract]   [Full Text] [Related]  

  • 24. A randomized trial of directly administered antiretroviral therapy and adherence case management intervention.
    Wohl AR; Garland WH; Valencia R; Squires K; Witt MD; Kovacs A; Larsen R; Hader S; Anthony MN; Weidle PJ
    Clin Infect Dis; 2006 Jun; 42(11):1619-27. PubMed ID: 16652320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early antiretroviral therapy: the role of cohorts.
    Sabin CA
    Curr Opin HIV AIDS; 2009 May; 4(3):200-5. PubMed ID: 19532051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Editorial comment: once-daily antiretroviral therapy.
    Boyle BA
    AIDS Read; 2002 Nov; 12(11):494-5. PubMed ID: 12498155
    [No Abstract]   [Full Text] [Related]  

  • 27. HIV therapy, guided by CD4 counts.
    Laurence J
    AIDS Read; 2006 Apr; 16(4):181-2. PubMed ID: 16617927
    [No Abstract]   [Full Text] [Related]  

  • 28. Assessing usual care in clinical trials of adherence interventions for highly active antiretroviral therapy.
    Wagner GJ; Kanouse DE
    J Acquir Immune Defic Syndr; 2003 Jun; 33(2):276-7. PubMed ID: 12794566
    [No Abstract]   [Full Text] [Related]  

  • 29. The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization.
    Sansom SL; Anthony MN; Garland WH; Squires KE; Witt MD; Kovacs Andrea A; Larsen RA; Valencia R; Pals SL; Hader S; Weidle PJ; Wohl AR
    AIDS Patient Care STDS; 2008 Feb; 22(2):131-8. PubMed ID: 18260804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Quality of life as the focus of modern anti-HIV treatment. More compact regimens for therapy success].
    MMW Fortschr Med; 2001 Sep; 143(35-36):58-9. PubMed ID: 11584536
    [No Abstract]   [Full Text] [Related]  

  • 31. Initial testing of the Antiretroviral Medication Complexity Index.
    DiIorio C; McDonnell M; McCarty F; Yeager K
    J Assoc Nurses AIDS Care; 2006; 17(1):26-36. PubMed ID: 16686082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medication persistence of HIV-infected drug users on directly administered antiretroviral therapy.
    Ing EC; Bae JW; Maru DS; Altice FL
    AIDS Behav; 2013 Jan; 17(1):113-21. PubMed ID: 22105340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.
    Wittkop L; Smith C; Fox Z; Sabin C; Richert L; Aboulker JP; Phillips A; Chêne G; Babiker A; Thiébaut R;
    Clin Trials; 2010 Feb; 7(1):19-35. PubMed ID: 20156955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiretroviral therapy of HIV infection. German-Austrian recommendations (July 2002).
    ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
    Eur J Med Res; 2003 Jun; 8(6):257-74. PubMed ID: 12918533
    [No Abstract]   [Full Text] [Related]  

  • 36. Antiretroviral regimens for treatment-experienced patients with HIV-1 infection.
    Lagnese M; Daar ES
    Expert Opin Pharmacother; 2008 Apr; 9(5):687-700. PubMed ID: 18345948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The risk of treatment versus the risk of HIV replication.
    Deeks SG
    Lancet; 2006 Jun; 367(9527):1955-6. PubMed ID: 16782465
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication.
    Altice FL; Mezger JA; Hodges J; Bruce RD; Marinovich A; Walton M; Springer SA; Friedland GH
    Clin Infect Dis; 2004 Jun; 38 Suppl 5():S376-87. PubMed ID: 15156426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial strategy for antiretroviral-naive patients.
    Abgrall S
    Lancet; 2006 Dec; 368(9553):2107-9. PubMed ID: 17174691
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.